{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"10.65","upperLimit":"13.41","value":"11.9"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"682"}],"units":"Participants"}],"description":"Overall survival was calculated as the time from study enrollment, defined as the IVRS enrollment date, until death due to any cause. Participants who did not have death data at the time of study end/analysis were censored at the time they were last known to be alive.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received 4 mg pomalidomide (POM) by mouth (PO) on Days 1 to 21 of each 28-day treatment cycle and low dose dexamethasone (LD-Dex) PO at the starting dose of 40 mg/day (≤ 75 years old) or 20 mg/day (\\> 75 years old) on Days 1, 8, 15 and 22 of a 28-day cycle until the documentation of confirmed progressive disease (PD), intolerable toxicity, death, withdrawal of participation in the study/consent, lost to follow-up, or as long as they benefited from therapy according to the opinion of the responsible study investigator.","id":"OG000","title":"Pomalidomide Plus Low Dose Dexamethasone (LD-Dex)"}],"paramType":"MEDIAN","populationDescription":"The intent to treat (ITT) population was defined as all enrolled participants (participants who received an interactive voice response system (IVRS) enrollment date) regardless of whether they received any investigational product (IP) or not.","reportingStatus":"POSTED","timeFrame":"From enrollment to the end of follow-up; median time on follow-up was 10.9 (range 0 - 81) months","title":"Kaplan Meier Estimate of Overall Survival (OS)","type":"SECONDARY","unitOfMeasure":"Months"}